Seventy patients (50.4 %) had both KRAS and BRAF wild-type metastatic colorectal cancer, and 62 patients fulfilled the inclusion criteria (45.2 % [28/62] female; median age 66 years [range 34–83 years]; Table 1) and were enrolled in the present study. Here, KRAS is linked to metastatic colorectal cancer.